No.

Publication Date

Citing Article

1

2025

Elyse A. Olesinski, Shruti Bhatt. Pandora’s Box of AML: How TP53 Mutations Defy Therapy and Hint at New Hope, Biomedicines. 2025; 13: 3007.  https://doi.org/10.3390/biomedicines13123007

2

2025

Zhigang Nian, Yingchao Dou, Haiming Wei. p53: An Immune Ecosystem Manipulator, Clinical Cancer Research. 2025; 31: 5120.  https://doi.org/10.1158/1078-0432.CCR-24-3628

3

2026

Kari J. T. Grünewald, Marjolein M. G. Kes, Gawin R. Stoll, Willem P. J. Cox, Dorette S. van Ingen Schenau, Enzo M. Scutigliani, Emmely M. Wagener, Ziqin Tang, Senna Visser, Jolanda Kooiman, Jessica Buijs‐Gladdines, Maria Rodionova, Esther A. Zaal, Jeroen W. A. Jansen, Jeroen F. van Velzen, Jarno Drost, Laurens T. van der Meer, Celia R. Berkers, Frank N. van Leeuwen. Combined inhibition of de novo pyrimidine synthesis and ATR promotes ATF4‐mediated cell death in TP53‐deficient ALL, HemaSphere. 2026; 10: e70439.  https://doi.org/10.1002/hem3.70439

4

2025

Sumel Ashique, Biplab Debnath, Mohhammad Ramzan, Tahreen Taj, Anas Islam, Priya Chaudhary, Monika Kaushik, Ashish Garg, Aniruddha Sen, Ciniraj Raveendran, Md Sadique Hussain, Robab Anbiaee, Farzad Taghizadeh-Hesary. A critical review of the synergistic potential of targeting p53 and CAR T cell therapy in cancer treatment, Biomedicine & Pharmacotherapy. 2025; 189: 118308118308.  https://doi.org/10.1016/j.biopha.2025.118308

5

2025

Larissa C. Zanetti, Victoria Tomaz, Ingrid Ferreira de Souza, Paulo V. Campregher, Nelson Hamerschlak, Lucila N. Kerbauy. Precision medicine with car cells in acute myeloid leukemia: where are we?, Frontiers in Immunology. 2025; 16: 1653350.  https://doi.org/10.3389/fimmu.2025.1653350

6

2026

Li Liu, Hanlu Wang, Lin Shi, Chao Zhang, Leshuai Zhang, Lulu Lv, Yongzeng Wang. Development of super Vδ2 T cells for relapsed/refractory acute myeloid Leukemia via non-viral site-specific integration, International Immunopharmacology. 2026; 185: 116981116981.  https://doi.org/10.1016/j.intimp.2026.116981